DOCSLIB.ORG

240 Part 522—Implantation Or Injectable Dosage Form

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
240 Part 522—Implantation Or Injectable Dosage Form § 520.2645 21 CFR Ch. I (4–1–14 Edition) feed; and for the control of porcine pro- (3) Limitations. Federal law restricts liferative enteropathies (PPE, ileitis) this drug to use by or on the order of a associated with Lawsonia intracellularis licensed veterinarian. when followed immediately by tylosin [77 FR 55415, Sept. 10, 2012] phosphate medicated feed. (B) For the treatment and control of PART 522—IMPLANTATION OR swine dysentery associated with Brachyspira hyodysenteriae. INJECTABLE DOSAGE FORM NEW (iii) Limitations. Prepare a fresh solu- ANIMAL DRUGS tion daily. Do not administer within 48 Sec. hours of slaughter. As indicated in 522.23 Acepromazine. paragraph (d)(3)(ii)(A) of this section, 522.52 Alfaxalone. follow with tylosin phosphate medi- 522.56 Amikacin. cated feed as in § 558.625(f)(1)(vi)(c) of 522.62 Aminopentamide. this chapter. 522.82 Aminopropazine. (4) Honey bees—(i) Amount. Mix 200 522.84 Beta-aminopropionitrile. milligrams tylosin in 20 grams confec- 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. tioners’/powdered sugar. Use imme- 522.90a Ampicillin trihydrate suspension. diately. Apply (dust) this mixture over 522.90b Ampicillin trihydrate powder for in- the top bars of the brood chamber once jection. weekly for 3 weeks. 522.90c Ampicillin sodium. (ii) Indications for use. For the control 522.144 Arsenamide. of American foulbrood (Paenibacillus 522.147 Atipamezole. 522.150 Azaperone. larvae). 522.161 Betamethasone. (iii) Limitations. The drug should be 522.163 Betamethasone dipropionate and fed early in the spring or fall and con- betamethasone sodium phosphate aque- sumed by the bees before the main ous suspension. honey flow begins, to avoid contamina- 522.204 Boldenone. tion of production honey. Complete 522.234 Butamisole. 522.246 Butorphanol. treatments at least 4 weeks before 522.275 N-Butylscopolammonium. main honey flow. 522.300 Carfentanil. 522.304 Carprofen. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.311 Cefovecin. FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, 522.313 Ceftiofur injectable dosage forms. 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, 522.313a Ceftiofur crystalline free acid. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.313b Ceftiofur hydrochloride. 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; 522.313c Ceftiofur sodium. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.380 Chloral hydrate, pentobarbital, and 17, 2012] magnesium sulfate. 522.390 Chloramphenicol. § 520.2645 Tylvalosin. 522.460 Cloprostenol. (a) Specifications. Granules containing 522.468 Colistimethate sodium powder for 62.5 percent tylvalosin (w/w) as injection. 522.480 Corticotropin. tylvalosin tartrate. 522.518 Cupric glycinate injection. (b) Sponsor. See No. 066916 in 522.522 Danofloxacin. § 510.600(c) of this chapter. 522.533 Deslorelin. (c) Related tolerances. See § 556.748 of 522.535 Desoxycorticosterone. this chapter. 522.536 Detomidine. 522.540 Dexamethasone solution. (d) Conditions of use in swine—(1) 522.542 Dexamethasone suspension. Amount. Administer 50 parts per mil- 522.558 Dexmedetomidine. lion tylvalosin in drinking water for 5 522.563 Diatrizoate. consecutive days. 522.650 Dihydrostreptomycin sulfate injec- (2) Indications for use. For the control tion. of porcine proliferative enteropathy 522.690 Dinoprost solution. 522.723 Diprenorphine. (PPE) associated with Lawsonia 522.770 Doramectin. intracellularis infection in groups of 522.775 Doxapram. swine in buildings experiencing an out- 522.784 Doxylamine. break of PPE. 522.800 Droperidol and fentanyl. 240 VerDate Mar<15>2010 09:09 Aug 04, 2014 Jkt 232075 PO 00000 Frm 00250 Fmt 8010 Sfmt 8010 Y:\SGML\232075.XXX 232075 wreier-aviles on DSK5TPTVN1PROD with CFR Food and Drug Administration, HHS Pt. 522 522.810 Embutramide, chloroquine, and lido- 522.1367 Meloxicam. caine solution. 522.1372 Mepivacaine. 522.812 Enrofloxacin. 522.1380 Methocarbamol. 522.814 Eprinomectin. 522.1410 Methylprednisolone. 522.820 Erythromycin. 522.1450 Moxidectin solution. 522.840 Estradiol. 522.1451 Moxidectin microspheres for injec- 522.842 Estradiol benzoate and testosterone tion. propionate. 522.1452 Nalorphine. 522.850 Estradiol valerate and norgestomet 522.1465 Naltrexone. in combination. 522.1468 Naproxen for injection. 522.863 Ethylisobutrazine. 522.1484 Neomycin. 522.870 Etodolac. 522.1503 Neostigmine. 522.883 Etorphine. 522.1610 Oleate sodium. 522.900 Euthanasia solution. 522.1620 Orgotein for injection. 522.914 Fenprostalene. 522.1660 Oxytetracycline injectable dosage 522.930 Firocoxib. forms. 522.955 Florfenicol. 522.1660a Oxytetracycline solution, 200 mil- 522.956 Florfenicol and flunixin. ligrams/milliliter. 522.960 Flumethasone injectable dosage 522.1660b Oxytetracycline solution, 300 mil- forms. ligrams/milliliter. 522.960a Flumethasone suspension. 522.1662 Oxytetracycline hydrochloride im- 522.960b Flumethasone acetate solution. plantation or injectable dosage forms. 522.960c Flumethasone solution. 522.1662a Oxytetracycline hydrochloride in- 522.970 Flunixin. jection. 522.995 Fluprostenol. 522.1662b Oxytetracycline hydrochloride 522.1002 Follicle stimulating hormone. with lidocaine injection. 522.1004 Fomepizole. 522.1662 Oxytetracycline and flunixin. 522.1010 Furosemide. 522.1680 Oxytocin. 522.1014 Gamithromycin. 522.1696 Penicillin G procaine injectable 522.1020 Gelatin. dosage forms. 522.1044 Gentamicin. 522.1696a Penicillin G benzathine and peni- 522.1066 Glycopyrrolate. cillin G procaine suspension. 522.1073 Gonadorelin acetate. 522.1696b Penicillin G procaine aqueous sus- 522.1075 Gonadorelin diacetate tetra- pension. hydrate. 522.1696c Penicillin G procaine in oil. 522.1077 Gonadorelin hydrochloride. 522.1698 Pentazocine. 522.1079 Serum gonadotropin and chorionic 522.1704 Pentobarbital. gonadotropin. 522.1720 Phenylbutazone. 522.1081 Chorionic gonadotropin for injec- 522.1820 Pituitary luteinizing hormone pow- tion; chorionic gonadotropin suspension. der for injection. 522.1083 Gonadotropin releasing factor ana- 522.1850 Polysulfated glycosaminoglycan. log-diphtheria toxoid conjugate. 522.1862 Pralidoxime powder for injection. 522.1085 Guaifenesin powder for injection. 522.1870 Praziquantel. 522.1086 Guaifenesin solution. 522.1881 Prednisolone acetate. 522.1125 Hemoglobin glutamer-200 (bovine). 522.1883 Prednisolone sodium phosphate. 522.1145 Hyaluronate. 522.1884 Prednisolone sodium succinate. 522.1150 Hydrochlorothiazide. 522.1885 Prednisolone tertiary butylacetate. 522.1155 Imidocarb powder for injection. 522.1890 Sterile prednisone suspension. 522.1156 Imidocarb solution. 522.1920 Prochlorperazine and isopropamide. 522.1160 Insulin. 522.1940 Progesterone and estradiol ben- 522.1182 Iron injection. zoate. 522.1185 Isoflupredone. 522.1962 Promazine. 522.1192 Ivermectin. 522.2002 Propiopromazine. 522.1193 Ivermectin and clorsulon. 522.2005 Propofol. 522.1204 Kanamycin. 522.2012 Prostalene. 522.1222 Ketamine. 522.2063 Pyrilamine. 522.1223 Ketamine, promazine, and 522.2076 Romifidine. aminopentamide. 522.2100 Selenium and vitamin E. 522.1225 Ketoprofen. 522.2112 Sometribove zinc suspension. 522.1242 Levamisole. 522.2120 Spectinomycin dihydrochloride in- 522.1260 Lincomycin. jection. 522.1289 Lufenuron. 522.2121 Spectinomycin sulfate. 522.1290 Luprostiol. 522.2150 Stanozolol. 522.1315 Maropitant. 522.2200 Sulfachlorpyridazine. 522.1335 Medetomidine. 522.2220 Sulfadimethoxine. 522.1350 Melatonin implant. 522.2240 Sulfaethoxypyridazine. 522.1362 Melarsomine powder for injection. 522.2260 Sulfamethazine. 241 VerDate Mar<15>2010 09:09 Aug 04, 2014 Jkt 232075 PO 00000 Frm 00251 Fmt 8010 Sfmt 8010 Y:\SGML\232075.XXX 232075 wreier-aviles on DSK5TPTVN1PROD with CFR § 522.23 21 CFR Ch. I (4–1–14 Edition) 522.2340 Sulfomyxin. venous injection over approximately 60 522.2404 Thialbarbitone sodium for injec- seconds or until clinical signs show the tion. onset of anesthesia, 2.2 to 9.7 mg/kilo- 522.2424 Thiamylal. gram (kg) for cats that did not receive 522.2444 Thiopental injectable dosage forms. 522.2444a Thiopental powder for injection. a preanesthetic or 1.0 to 10.8 mg/kg for 522.2444b Thiopental and pentobarbital pow- cats that received a preanesthetic. der for injection. (B) Maintenance of general anesthesia 522.2460 Tildipirosin. following induction. Administer an in- 522.2470 Tiletamine and zolazepam for injec- travenous bolus containing 1.1 to 1.3 tion. mg/kg to provide an additional 7 to 8 522.2471 Tilmicosin. minutes of anesthesia in 522.2473 Tiludronate. preanesthetized cats; a dose containing 522.2474 Tolazoline. 1.4 to 1.5 mg/kg provides an additional 522.2476 Trenbolone acetate. 522.2477 Trenbolone acetate and estradiol. 3 to 5 minutes anesthesia in 522.2478 Trenbolone acetate and estradiol unpreanesthetized cats. benzoate. (ii) Dogs—(A) Induction of general an- 522.2483 Triamcinolone. esthesia. Administer by intravenous in- 522.2582 Triflupromazine. jection over approximately 60 seconds 522.2610 Trimethoprim and sulfadiazine. or until clinical signs show the onset of 522.2615 Tripelennamine. anesthesia, 1.5 to 4.5 mg/kg for dogs 522.2630 Tulathromycin. that did not receive a preanesthetic or 522.2640 Tylosin. 0.2 to 3.5 mg/kg for dogs that received 522.2662 Xylazine. 522.2670 Yohimbine. a preanesthetic. 522.2680 Zeranol. (B) Maintenance of general anesthesia 522.2690 Zinc gluconate. following induction. Administer an in- travenous bolus containing 1.2 to 1.4 AUTHORITY: 21 U.S.C. 360b. mg/kg to provide an additional 6 to 8 SOURCE: 40 FR 13858, Mar. 27, 1975, unless minutes of anesthesia in otherwise noted. preanesthetized
Load more

Recommended publications
  • 268 Part 522—Implantation Or Injectable Dosage Form
    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
    [Show full text]
  • Effects of Alfaxalone Or Propofol on Giant-Breed Dog Neonates Viability
    animals Article Effects of Alfaxalone or Propofol on Giant-Breed Dog Neonates Viability During Elective Caesarean Sections Monica Melandri 1, Salvatore Alonge 1,* , Tanja Peric 2, Barbara Bolis 3 and Maria C Veronesi 3 1 Società Veterinaria “Il Melograno” Srl, 21018 Sesto Calende, Varese, Italy; [email protected] 2 Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine, 33100 Udine, Italy; [email protected] 3 Department of Veterinary Medicine, Università degli Studi di Milano, 20100 Milan, Italy; [email protected] (B.B.); [email protected] (M.C.V.) * Correspondence: [email protected]; Tel.: +39-392-805-8524 Received: 20 September 2019; Accepted: 7 November 2019; Published: 13 November 2019 Simple Summary: Nowadays, thanks to the increased awareness of owners and breeders and to the most recent techniques available to veterinarians, the management of parturition, especially of C-sections, has become a topic of greater importance. Anesthesia is crucial and must be targeted to both the mother and neonates. The present study aimed to evaluate the effect of the induction agent alfaxalone on the vitality of puppies born from elective C-section, in comparison to propofol. After inducing general anesthesia for elective C-section, puppies from the mothers induced with alfaxalone had higher 5-min Apgar scores than those induced with propofol. The concentration of cortisol in fetal fluids collected at birth is neither influenced by the anesthetic protocol used, nor does it differ between amniotic and allantoic fluids. Nevertheless, the cortisol concentration in fetal fluids affects the relationship between anesthesia and the Apgar score: the present study highlights a significant relationship between the anesthetic protocol used and Apgar score in puppies, and fetal fluids cortisol concentration acts as a covariate of this relationship.
    [Show full text]
  • The Cardiorespiratory and Anesthetic Effects of Clinical and Supraclinical
    THE CARDIORESPIRATORY AND ANESTHETIC EFFECTS OF CLINICAL AND SUPRA CLINICAL DOSES OF ALF AXALONE IN CYCLODEXTRAN IN CATS AND DOGS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Laura L. Nelson, B.S., D.V.M. * * * * * The Ohio State University 2007 Dissertation Committee: Professor Jonathan Dyce, Adviser Professor William W. Muir III Professor Shane Bateman If I have seen further, it is by standing on the shoulders of giants. lmac Ne1vton (1642-1727) Copyright by Laura L. Nelson 2007 11 ABSTRACT The anesthetic properties of steroid hormones were first identified in 1941, leading to the development of neurosteroids as clinical anesthetics. CT-1341 was developed in the early 1970’s, featuring a combination of two neurosteroids (alfaxalone and alphadolone) solubilized in Cremophor EL®, a polyethylated castor oil derivative that allows hydrophobic compounds to be carried in aqueous solution as micelles. Though also possessing anesthetic properties, alphadolone was included principally to improve the solubility of alfaxalone. CT-1341, marketed as Althesin® and Saffan®, was characterized by smooth anesthetic induction and recovery in many species, a wide therapeutic range, and no cumulative effects with repeated administration. Its cardiorespiratory effects in humans and cats were generally mild. However, it induced severe hypersensitivity reactions in dogs, with similar reactions occasionally occurring in cats and humans. The hypersensitivity reactions associated with this formulation were linked to Cremophor EL®, leading to the discontinuation of Althesin® and some other Cremophor®-containing anesthetics. More recently, alternate vehicles for hydrophobic drugs have been developed, including cyclodextrins.
    [Show full text]
  • Intravenous Alfaxalone Anaesthesia in Two Squamate Species: Eublepharis Macularius and Morelia Spilota Cheynei
    INTRAVENOUS ALFAXALONE ANAESTHESIA IN TWO SQUAMATE SPECIES: EUBLEPHARIS MACULARIUS AND MORELIA SPILOTA CHEYNEI Tesi per il XXIX Ciclo del Dottorato in Scienze Veterinarie, Curriculum Scienze Cliniche Veterinarie Dipartimento di Scienze Veterinarie, Universita’ degli Studi di Messina Tutor: Prof. Filippo Spadola Cotutor: Prof. Zdenek Knotek Dr. Manuel Morici Sommario L’anestesia negli Squamati è una costante sfida della medicina e chirurgia dei rettili. Le differenze morfo-fisiologiche di questi taxa, rendono difficilmente applicabile i comuni concetti di anestesiologia veterinaria usati con successo negli altri animali da compagnia. Diversi protocolli anestetici sono stati utilizzati, sia per l’induzione che per il mantenimento, sia negli ofidi che nei sauri, ma con risultati variabili. Di fatti la maggior parte dei protocolli risultano in induzione o recuperi troppo brevi o troppo lunghi. L’obbiettivo di questa tesi dottorale è di valutare l’efficacia di un anestetico steroideo (alfaxalone), somministrato per via endovenosa in due specie di squamati usati come modello: il geco leopardo (Eublepharis macularius) e il pitone tappeto (Morelia spilota cheynei). Due metodi di somministrazione endovenosa (vena giugulare nei gechi e vena caudale nei serpenti) sono stati analizzati e descritti, usando un dosaggio di anestetico di 5 mg/kg in 20 gechi leopardo, e di 10 mg/kg in 10 pitoni tappeto. Nei gechi il tempo di induzione, il tempo di perdita del tono mandibolare, l’intervallo di anestesia chirurgica e il recupero completo sono stati rispettivamente di 27.5 ± 30.7 secondi, 1.3 ± 1.4 minuti, 12.5 ± 2.2 minuti and 18.8 ± 12.1 minuti. Nei pitoni tappeto, il tempo di induzione, la perdita di sensazione, il tempo di inserimento del tubo endotracheale, l’intervallo di anestesia chirurgica e il recupero sono stati rispettivamente di 3.1±0.8 minuti, 5.6±0.7 minuti, 6.9±0.9 minuti, 18.8±4.7 minuti, e 36.7±11.4 minuti.
    [Show full text]
  • Anesthesia During Gestation and Its Effects on Newborn
    Scientific Works. Series C. Veterinary Medicine. Vol. LXIII (1) ISSN 2065-1295; ISSN 2343-9394 (CD-ROM); ISSN 2067-3663 (Online); ISSN-L 2065-1295 increased cardiac work, and decreased an endotheliochorial and zonary type of peripheral vascular resistance. Other changes placenta (Miglino et al., 2006; Furukawa et al., ANESTHESIA DURING GESTATION AND ITS EFFECTS are respiratory, represented by decreased FRC, 2014). Most anesthetics cross the placenta and ON NEWBORN VIABILITY decreased total lung volume, increased minute the blood-brain barrier of the fetus. The ventilation and oxygen consumption, and permeability of the placenta differs depending Andra DEGAN, Dragoș BÎRȚOIU, Alexandru ȘONEA, Ruxandra COSTEA decreased PaCO2 (Ryan, Wagner, 2006; on type of placenta and the physicochemical Lemke, 2007; Branson, 2007). Dams and properties of the drugs. The endotheliochorial University of Agronomic Science and Veterinary Medicine, Faculty of Veterinary Medicine fetuses have an increased metabolic demand, placenta present in canines allows close Bucharest, 59 Marasti Blvd., District 1, Bucharest, Romania leading to a maternal blood volume increases maternal-fetal contact which facilitates the of approximately 40%. Plasma volume increase passive passage of drugs. Placental transfer of Corresponding author email: [email protected] is proportionally greater than the increase in drugs can occur by several mechanisms; by far, erythrocytes, leading to hemodilution and the most important is simple diffusion. Abstract: relative anemia (Seymour, 1999; Pascoe, Diffusion across the placenta is determined by During the gestation period, canine females go through physiological changes which can influence the way the Moon, 2001). A greater number of fetuses will molecular weight, the degree to which the drug anesthetics are absorbed, metabolized and excreted.
    [Show full text]
  • Alfaxan® User Guide
    Repeatable. Reliable. Relax. Alfaxan® User Guide Pre-anaesthetic assessment to recovery PRE-ANAESTHETIC ASSESSMENT INDUCTION TRANSITION Full clinical examination Draw up the full dose of Alfaxan® Connect to appropriate breathing system 2 mg/kg (0.2 mL/kg) for dogs CHECK FOR... LOOK OUT Suitable for anaesthesia? 5 mg/kg (0.5mL/kg) for cats FOR... 4 mg/kg (0.4 mL/kg) for rabbits YES NO Label the syringe Spontaneous ventilation? Take a ‘pre-induction’ Assign ASA score Further tests? heart rate YES NO Stabilise ASA PHYSICAL STATUS Re-assess CLASSIFICATION SYSTEM (Consider referral?) Secure IV access Ensure catheter is The five physical risk states are: intravenous and patent Supply maintenance Wait. If SPO2 ASA Physical Status 1 A normal healthy patient • Early plane of sedation agent and / or clinical signs indicate the ASA Physical Status 2 A patient with mild systemic disease Give ¼ of the induction dose • Degree of control Breathing need, start IPPV ASA Physical Status 3 A patient with severe systemic disease over the animal (Likely to be continuous) ASA Physical Status 4 A patient with severe systemic disease that is WAIT 15 SECONDS Heart Rate a constant threat to life (Alfaxan® is thought to LOOK OUT FOR... ASA Physical Status 5 A moribund patient who is not expected to Give another ¼ dose minimally affect cardiac survive without the operation function at clinical doses) If the animal has been presented as an emergency, the letter ‘E’ can be added to the recorded stage. WAIT 15 SECONDS Anaesthetic Depth • Adequate duration of action for It is essential that all patients are classified before any premedication is applied, and that smooth & unhurried transition consideration is paid to the classification in developing the patient’s anaesthetic protocol.
    [Show full text]
  • Accepted Manuscript
    Accepted Manuscript A clinical evaluation of the pharmacokinetics and pharmacodynamics of intravenous alfaxalone in cyclodextrin in male and female rats following a loading dose and constant rate infusion Kate L. White, Stuart Paine, John Harris PII: S1467-2987(17)30062-4 DOI: 10.1016/j.vaa.2017.01.001 Reference: VAA 88 To appear in: Veterinary Anaesthesia and Analgesia Please cite this article as: White KL, Paine S, Harris J, A clinical evaluation of the pharmacokinetics and pharmacodynamics of intravenous alfaxalone in cyclodextrin in male and female rats following a loading dose and constant rate infusion, Veterinary Anaesthesia and Analgesia (2017), doi: 10.1016/ j.vaa.2017.01.001. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. provided by Nottingham ePrints View metadata, citation and similar papers at core.ac.uk CORE brought to you by 1 ACCEPTED MANUSCRIPT 1 RESEARCH PAPER 2 A clinical evaluation of the pharmacokinetics and pharmacodynamics of 3 intravenous alfaxalone in cyclodextrin in male and female rats following a loading 4 dose and constant rate infusion 5 Kate L White*, Stuart Paine* & John Harris† 6 7 *School of Veterinary Medicine and Science, University of Nottingham, Sutton 8 Bonington, UK 9 †School of Biosciences, University of Nottingham, Sutton Bonington, UK 10 11 Correspondence: Kate White, School of Veterinary Medicine and Science, University 12 of Nottingham, Sutton Bonington, Loughborough, Leics LE12 5RD, UK.
    [Show full text]
  • Alfaxalone Activates Human Pregnane-X Receptors with Greater Efficacy Than Allopregnanolone: an In-Vitro Study with Implications for Neuroprotection During Anesthesia
    bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284075; this version posted September 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. 1 Alfaxalone activates Human Pregnane-X Receptors with greater efficacy than Allopregnanolone: an in-vitro study with implications for neuroprotection during anesthesia. Juliet.M. Serrao PhD¶, and Colin.S. Goodchild PhD*,¶, Drawbridge Pharmaceuticals Pty Ltd, Malvern, Victoria, Australia *Corresponding Author: Email: [email protected] (CSG) ¶ These authors contributed equally to this work: planning of the experiments; collating and analyzing data; writing of the manuscript. Data presented herein were submitted to the meeting of the International Research Society planned for May 2020 but then cancelled because of COVID19 pandemic Funding This project was funded by Drawbridge Pharmaceuticals Pty Ltd. Abbreviated Title: alfaxalone activates pregnane-X receptors Conflicts of Interests Juliet M Serrao and Colin S Goodchild both have equity interests in Drawbridge Pharmaceuticals. Both are cited on Phaxan™ patents as inventors and they are both Directors and owners of Drawbridge Pharmaceuticals to which the Phaxan™ patents have been assigned. Abstract Background Alfaxalone is a fast acting intravenous anesthetic with high therapeutic index. It is an analogue of the naturally-occurring neurosteroid, allopregnanolone which has been bioRxiv preprint doi: https://doi.org/10.1101/2020.09.05.284075; this version posted September 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • ALFAXAN MULTIDOSE- Alfaxalone Injection, Solution Jurox Pty
    ALFAXAN MULTIDOSE- alfaxalone injection, solution Jurox Pty. Limited ---------- ALFAXAN MULTIDOSE NADA 141-342, Approved by FDA For Animal Use Only Alfaxan® Multidose CIV (alfaxalone) 10 mg/mL Intravenous injectable anesthetic for use in cats and dogs CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian. DESCRIPTION ALFAXAN MULTIDOSE (alfaxalone) is a neuroactive steroid molecule with properties of a general anesthetic. Alfaxalone is chemically described as 3-α-hydroxy-5-α-pregnane-11, 20-dione, and has a molecular weight 332.5. The primary mechanism for the anesthetic action of alfaxalone is modulation of neuronal cell membrane chloride ion transport, induced by binding of alfaxalone to GABAA (gamma- aminobutyric acid) cell surface receptors. INDICATIONS ALFAXAN MULTIDOSE is indicated for the induction and maintenance of anesthesia and for induction of anesthesia followed by maintenance with an inhalant anesthetic, in cats and dogs. DOSAGE AND ADMINISTRATION Administer by intravenous injection only. For induction, administer ALFAXAN MULTIDOSE over approximately 60 seconds or until clinical signs show the onset of anesthesia, titrating administration against the response of the patient. Rapid administration of ALFAXAN MULTIDOSE may be associated with an increased incidence of cardiorespiratory depression or apnea. Apnea can occur following induction or after the administration of maintenance boluses of ALFAXAN MULTIDOSE. The use of preanesthetics may reduce the ALFAXAN MULTIDOSE induction dose. The choice and the amount of phenothiazine, alpha2-adrenoreceptor agonist, benzodiazepine or opioid will influence the response of the patient to an induction dose of ALFAXAN MULTIDOSE. When using ALFAXAN MULTIDOSE, patients should be continuously monitored, and facilities for the maintenance of a patent airway, artificial ventilation, and oxygen supplementation must be immediately available.
    [Show full text]
  • Chapter 3 T&L
    Chapter 3 Anesthetic Agents and Adjuncts 1 Chapter 3 Anesthetic Agents and Adjuncts Propofol, etomidate, and alfaxalone are used only in small animals, small ruminants, and neonates of any species, but not in adult large animals because of the high expense of these agents. The ultra-short injectable barbiturate anesthetics are no longer used in general practice in the US due to recent changes in anesthetic practice and limited availability. 2 Chapter 3 Anesthetic Agents and Adjuncts Since its introduction to the veterinary market almost two decades ago, its popularity has gradually increased, and now it is the most commonly used ultra– short-acting injectable agent in small animals for brief procedures or for anesthetic induction before intubation and maintenance with inhalant agents. 3 Chapter 3 Anesthetic Agents and Adjuncts The propofol macroemulsion contains propofol at a concentration of 10 mg/mL as well as egg lecithin, glycerin, and soybean oil. It has a milky appearance but is given by the IV route and consequently is the sole exception to the general rule that milky liquids should never be given intravenously. Although the mode of action is not completely understood, propofol appears to affect GABA receptors in a similar manner to other hypnotics. Propofol has a rapid onset and short duration of action because it is highly fat-soluble. Propofol is rapidly taken up by vessel-rich tissues such as the brain, heart, liver, and kidneys but is very quickly redistributed to muscle and fat and is subsequently rapidly metabolized. This accounts for the rapid recovery and minimal residual sedative effects seen even after repeated injections.
    [Show full text]
  • Federal Register/Vol. 78, No. 57/Monday, March 25, 2013
    Federal Register / Vol. 78, No. 57 / Monday, March 25, 2013 / Proposed Rules 17895 22,109 hours due to this proposed 1. The panel transcript and other being placed in commercial regulatory change. meeting materials are available on distribution. FDA’s Web site at http://www.fda.gov/ IX. Proposed Effective Date Dated: March 19, 2013. AdvisoryCommittees/ Leslie Kux, FDA is proposing that any final order CommitteesMeetingMaterials/ Assistant Commissioner for Policy. based on this proposal become effective MedicalDevices/ on the date of its publication in the MedicalDevicesAdvisoryCommittee/ [FR Doc. 2013–06723 Filed 3–22–13; 8:45 am] Federal Register or at a later date if CirculatorySystemDevicesPanel/ BILLING CODE 4160–01–P stated in the final order. ucm240575.htm. X. Codification of Orders List of Subjects in 21 CFR Part 870 DEPARTMENT OF JUSTICE Prior to the amendments by FDASIA, Medical devices. section 515(b) of the FD&C Act provided Drug Enforcement Administration Therefore, under the Federal Food, for FDA to issue regulations to require Drug, and Cosmetic Act and under approval of an application for premarket 21 CFR Part 1308 authority delegated to the Commissioner approval for preamendments devices or of Food and Drugs, it is proposed that [Docket No. DEA–370] devices found substantially equivalent 21 CFR part 870 be amended as follows: to preamendments devices. Section Schedules of Controlled Substances: 515(b) of the FD&C Act, as amended by PART 870—CARDIOVASCULAR Placement of Alfaxalone into Schedule FDASIA, provides for FDA to require DEVICES IV approval of an application for premarket AGENCY: approval for such devices by issuing a ■ 1.
    [Show full text]
  • A Review of the Pharmacology and Clinical Application of Alfaxalone in Cats Leon N
    ARTICLE IN PRESS The Veterinary Journal ■■ (2015) ■■–■■ Contents lists available at ScienceDirect The Veterinary Journal journal homepage: www.elsevier.com/locate/tvjl Review A review of the pharmacology and clinical application of alfaxalone in cats Leon N. Warne, Thierry Beths, Ted Whittem, Jennifer E. Carter, Sébastien H. Bauquier * Translational Research and Clinical Trials (TRACTs), Veterinary Hospital, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, Vic 3030, Australia ARTICLE INFO ABSTRACT Article history: Alfaxalone-2-hydroxpropyl-β-cyclodextrin (alfaxalone-HPCD) was first marketed for veterinary use in Aus- Accepted 14 December 2014 tralia in 2001 and has since progressively became available throughout the world, including the USA, where in 2012 Food and Drug Administration (FDA) registration was granted. Despite the growing body Keywords: of published works and increasing global availability of alfaxalone-HPCD, the accumulating evidence for Alfaxalone its use in cats has not been thoroughly reviewed. The purpose of this review is: (1) to detail the phar- Feline macokinetic properties of alfaxalone-HPCD in cats; (2) to assess the pharmacodynamic properties of Anaesthesia alfaxalone-HPCD, including its cardiovascular, respiratory, central nervous system, neuromuscular, hepatic, Pharmacology Intravenous anaesthesia renal, haematological, blood-biochemical, analgesic and endocrine effects; and (3) to consider the clin- ical application of alfaxalone-HPCD for sedation, induction and maintenance of anaesthesia in cats. Based on the published literature, alfaxalone-HPCD provides a good alternative to the existing intravenous an- aesthetic options for healthy cats. © 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
    [Show full text]